Search Results - "Raphael, Ari"
-
1
Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional study
Published in BMC medical research methodology (07-01-2022)“…Clinical trials are an essential source for advances in oncologic care, yet the enrollment rate is only 2-4%. Patients' reluctance to participate is an…”
Get full text
Journal Article -
2
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
Published in Frontiers in oncology (13-05-2022)“…Background The use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable. Methods We prospectively assessed the…”
Get full text
Journal Article -
3
Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?
Published in Life (Basel, Switzerland) (20-08-2022)“…The association between anthracycline (ANT) and left ventricle (LV) dysfunction is well known; however, data regarding its direct effect on cardiac valve…”
Get full text
Journal Article -
4
GENOMIC PROFILING IN LUMINAL BREAST CANCER
Published in הרפואה (01-02-2022)“…Genomic profiling of breast cancer, with the use of microarrays shows that breast cancer is a group of different diseases. For example, estrogen receptor (ER)…”
Get more information
Journal Article -
5
Body composition measures as a determinant of alpelisib-related toxicity
Published in Journal of clinical oncology (01-06-2024)“…e13093 Background: Body composition has emerged as an important prognostic factor in patients treated with cancer. Severe depletion of skeletal muscle,…”
Get full text
Journal Article -
6
Body composition measures as a determinant of Alpelisib related toxicity
Published in Breast cancer research and treatment (01-07-2024)“…Background Body composition has emerged as an important prognostic factor in patients treated with cancer. Severe depletion of skeletal muscle, sarcopenia, has…”
Get full text
Journal Article -
7
Abstract P5-13-19: Sarcopenia and skeletal muscle density as predictors of toxicity in patients with metastatic breast cancer receiving alpelisib
Published in Cancer research (Chicago, Ill.) (15-02-2022)“…Abstract Background: Poor body composition metrics (BCM) are associated with inferior cancer outcomes. Alpelisib, a PIK3CA inhibitor, is increasingly used in…”
Get full text
Journal Article -
8
Body composition measures as predictors of toxicity in patients with metastatic breast cancer receiving PARP inhibitors
Published in Journal of clinical oncology (01-06-2023)“…e13010 Background: Poor body composition metrics (BCM), such as high adiposity or low muscle mass, are associated with inferior cancer outcomes. Poly…”
Get full text
Journal Article -
9
A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors
Published in Journal of clinical oncology (20-05-2020)“…Abstract only TPS3160 Background: Immunotherapy with the anti-PD-(L)1 checkpoint inhibitors (CPIs) has been largely ineffective in so-called non-immunogenic…”
Get full text
Journal Article -
10
High neutrophil‐to‐lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline
Published in Clinical cardiology (Mahwah, N.J.) (01-03-2023)“…Background Cardiotoxicity, defined mainly as left ventricle (LV) dysfunction, is a significant side effect of anthracyclines (ANT) therapy. The need for an…”
Get full text
Journal Article -
11
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
Published in Genes (29-09-2022)“…This real-world cohort analysis assessed the efficacy of alpelisib and endocrine treatment (ET) combinations in a post-everolimus setting. Thirteen women who…”
Get full text
Journal Article -
12
Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis
Published in Clinical research in cardiology (2021)“…Background Immune checkpoint inhibitors (ICI) have transformed the standard care of cancer treatment. Recent case reports describe ICI-mediated myocarditis…”
Get full text
Journal Article -
13
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2 nd /3 rd -Generation ALK Tyrosine Kinase Inhibitors (TKIs)
Published in Frontiers in oncology (2022)“…The use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable. We prospectively assessed the impact of CGP on…”
Get full text
Journal Article -
14
Abstract CT205: Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
Published in Cancer research (Chicago, Ill.) (14-04-2023)“…Abstract Background: NAP is a chimeric protein composed of a superantigen (SAg) and a Fab targeting the common tumor antigen 5T4. Its therapeutic effect is…”
Get full text
Journal Article -
15
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Published in Journal of clinical medicine (28-04-2022)“…fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their…”
Get full text
Journal Article